Iniparib in metastatic triple-negative breast cancer

New England Journal of Medicine

Volumn 364, Issue 18, 2011, Pages 1780-1781

  Domagala, Pawel ^a   Lubinski, Jan ^a   Domagala, Wenancjusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; INIPARIB; POLYADENOSINE DIPHOSPHATE RIBOSE POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; 4 IODO 3 NITROBENZAMIDE; 4-IODO-3-NITROBENZAMIDE; BENZAMIDE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN;

BREAST CANCER; BREAST METASTASIS; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; METABOLISM; METASTASIS; NOTE; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 79955731161     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1101855     Document Type: Letter

References (4)

1. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14.
2. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
3. Domagala P, Huzarski T, Lubinski J, Gugata K, Domagala W. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 2011;458:55-64.
4. Domagala P, Huzarski T, Lubinski J, et al. PARP expression in breast cancer including BRCA1-associated, triple-negative and basal-like tumours: implications for anti-PARP1 therapy. Breast Cancer Res Treat 2011 March 17 (Epub ahead of print).